A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade 3 (CIN3), according to results from ...

The phase III, randomized, controlled Papilloma Trial Against Cancer in Young Adults (PATRICIA) showed that the HPV-16/18 vaccine has enhanced immunogenicity when aluminium hydroxide and ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.

Getting the HPV vaccine in early adolescence may lower the risk of HPV-related cancers before exposure occurs. Learn about ...

“Our findings demonstrate that the therapeutic vaccine Vvax001 is safe, well-tolerated, and effective in eradicating HPV16-associated CIN3 lesions and clearing the underlying persistent HPV16 ...

However, if a woman is found to be HPV positive with a high-risk strand (HPV 16 and/or 18), also referred to as a high-grade lesion, she will then be sent for further testing right away.

Fewer than half of patients testing positive for HPV received recommended annual follow-up testing, a new cohort study found.

Among female patients with positive human papillomavirus (HPV) test results and negative intraepithelial lesion or malignancy ...